Cysteine Leukotriene Receptor Antagonist—Montelukast—Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice
2024

Montelukast Improves Abdominal Aortic Aneurysms in Mice

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Li Kexin, Li Meng, Wei Panpan, Tian Kangli, Liu Haole, Fu Weilai, Hou Haiwen, Chen Yajie, Xu Baohui, Li Yankui, Zhao Sihai

Primary Institution: Xi'an Jiaotong University Health Science Center

Hypothesis

Montelukast may improve nondissecting abdominal aortic aneurysms by inhibiting aortic inflammation.

Conclusion

Montelukast treatment improves experimental nondissected abdominal aortic aneurysms in mice partly by improving aortic inflammation.

Supporting Evidence

  • Montelukast significantly decreased aortic expansion in a dose-dependent manner.
  • Histopathological analysis showed improved aortic elastin degradation with montelukast treatment.
  • Montelukast reduced local leucocyte infiltration in aortic aneurysmal lesions.
  • Montelukast downregulated MMP2 and MMP9 expression in aneurysmal aortas.
  • Montelukast treatment decreased mural neovessel density in the aorta.

Takeaway

Montelukast, a medicine usually for asthma, helps mice with a serious blood vessel problem by reducing inflammation.

Methodology

Nondissecting AAAs were induced in mice using porcine pancreatic elastase, followed by treatment with montelukast or vehicle for 14 days.

Limitations

Only the PPE-induced model was used; other models should be tested to confirm results.

Participant Demographics

Thirty male C57BL/6J mice, aged 9-12 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2024/8826287

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication